

Index

- ablation, 168
 - cryoablation, 175, 198–9
 - cryotherapy, 168–9
 - fine needle (FNAB), 119–20
 - high intensity focused ultrasound (HIFU), 169
 - laser photocoagulation, 169
 - limitations and challenges
 - image-guidance and tumor targeting, improved, 176–7
 - inadequate treatment identification and rectification of, 177–81
 - probe development and adjunctive interventions, 175–6
 - thermal injury to adjacent or critical structures, reducing, 176
 - radiofrequency (RFA), 30, 169–75
 - post-RFA surveillance, 196–7
 - results, 173–5
 - techniques, 170–1
 - troubleshooting, 171–3
- adenoma, 19–20
- ADPKD, *see* autosomal dominant polycystic kidney disease (ADPKD)
- adrenalectomy, 157
 - see also* surgery
- adrenal invasion, 102–3
 - see also* M staging
- adult renal parenchymal cancers, 17
- AIDS-related lymphoma (ARL), 148–9
- algorithms, prognostic, 26
 - biopsy for renal mass characterization, 27
 - established indications for biopsy, 28
 - extrarenal cancer patients, 28
 - patients with possible infections, 29
 - molecular markers, 27
 - renal cancer subtypes grouped, 26
 - systems for conventional (clear cell), clinically localized carcinoma, 26–7
- angiomyolipomas (AMLs), 65
 - macroscopic fat-containing, 75–6
 - minimal fat containing, 78
- ARL, *see* AIDS-related lymphoma (ARL)
- autosomal dominant polycystic kidney disease (ADPKD), 51
- benign tumors, 29–30
 - see also* biopsy
- BHD, *see* Birt–Hogg–Dubé (BHD) syndrome
- biomarkers, RCC, 5
- biopsy, 112
 - for benign tumors, 29–30
 - focal renal
 - complications after focal renal biopsy, 121
 - contemporary indications for, 113
 - core biopsy versus fine needle ablation, 119–20
 - diagnostic performance of, 118–20
 - focal cystic tumor renal biopsy, 120
 - focal solid renal biopsy, 118–20
 - for indeterminate masses, 30–1
 - for patients undergoing radio-frequency ablation, 30
 - for renal mass characterization, 27
 - established indications for biopsy, 28
 - extrarenal cancer patients, 28
 - patients with possible infections, 29
 - technique, 113–18
- Birt–Hogg–Dubé (BHD) syndrome
 - clinical features, 45–6
 - genetics, 45
 - imaging, 46
 - see also* von Hippel–Lindau (VHL) syndrome
- bone tumor recurrence, 187–8
 - see also* recurrent tumor
- Bosniak cyst classification system, 71–4
 - see also* simple renal cysts
- CAIX, *see* carbonic anhydrase isoenzyme (CAIX)
- cancer patients, extrarenal, 28
- carbonic anhydrase isoenzyme (CAIX), 5
- carcinoma
 - clinically localized, 26–7
 - versus adenoma, 19–20
 - versus oncocytoma, 20

228 Index

- CCRCC, *see* clear cell renal cell carcinoma (CCRCC)
 CDRCC, *see* collecting duct carcinomas (CDRCC)
 CFRT, *see* conformal radiotherapy (CFRT)
 chemotherapy, 1
 see also hormonal therapies; immunochemotherapy, RCC; immunotherapy
 chromophobe RCC (CHRCC), 131
 chromosome 3, translocation of
 clinical features, 55
 genetics, 55
 imaging, 55
 chronic kidney disease, 211–13
 see also nephron-sparing surgery (NSS)
 clear cell renal cell carcinoma (CCRCC), 26–7, 127
 clinical features
 Birt–Hogg–Dubé syndrome, 45–6
 familial renal oncocytoma, 54
 hereditary leiomyomatosis renal cell carcinoma (HLRCC), 49
 hereditary papillary renal carcinoma, 47–8
 hyperparathyroidism-jaw tumor (HPT-JT) syndrome, 53
 medullary carcinoma of kidney, 55
 translocation of chromosome 3, 55
 tuberous sclerosis complex (TSC), 51
 von Hippel–Lindau syndrome, 41–2
 clinically localized carcinoma, 26–7
 see also adenoma; oncocytoma
 clinical risk stratification, RCC, 3–5
 CMP, *see* corticomedullary phase (CMP)
 collecting duct carcinomas (CDRCC), 131–2
 collecting system invasion, renal tumor and, 26
 complex renal cysts, 71–4
 see also simple renal cysts
 computed tomography (CT), 1
 multi-detector (MDCT), 64–8, 97
 nephron-sparing surgery and, 203–8
 for renal cancer diagnosis, 64–5
 renal lymphoma patterns
 contiguous retroperitoneal extension, 145, 146
 diffuse renal enlargement, 144
 multiple masses, 143
 perirenal renal mass, 145
 solitary renal mass, 144
 staging and, 93
 venous invasion assessment and, 97–9
 see also imaging; positron emission tomography (PET)
 conformal radiotherapy (CFRT), 7
 contiguous retroperitoneal extension, 145–6
 contralateral kidney tumor recurrence, 188–9
 see also recurrent tumor
 contrast kidney disease, 211–13
 see also nephron-sparing surgery (NSS)
 corticomedullary phase (CMP), 65–6
 cryoablation, 168–9, 175, 198–9
 see also radiofrequency ablation (RFA)
 cystic tumor renal biopsy, focal, 120
 cysts, renal
 complex, 71–4
 simple, 71
 de-enhancement, 69
 see also radiological diagnosis of renal cancer
 diffuse renal enlargement, 144
 electron microscopy, 21
 see also renal tumor
 enhancement
 assessing masses for, 68–9
 limitations, 69–70
 phases
 corticomedullary phase (CMP), 65–6
 excretory phase (EP), 65–6
 nephrographic phase (NP), 65–6
 vascular phase (VP), 65–6
 see also radiological diagnosis of renal cancer
 enlargement, diffuse renal, 144
 epidemiology, RCC, 1, 2
 excretory phase (EP), 65–6
 extension, contiguous retroperitoneal, 145–6
 extrarenal cancer patients, 28
 familial renal cancers, 38
 Birt–Hogg–Dubé syndrome, 45–6
 familial renal oncocytoma, 54
 hereditary, *see* hereditary renal cancer
 hereditary leiomyomatosis renal cell carcinoma (HLRCC), 49
 hereditary papillary renal carcinoma, 47–8
 hyperparathyroidism-jaw tumor (HPT-JT) syndrome, 53
 inherited, *see* inherited renal cancer
 medullary carcinoma of kidney, 55
 oncocytoma (FRO)
 clinical features, 54
 genetics, 54
 imaging, 54
 translocation of chromosome 3, 55
 tuberous sclerosis complex (TSC), 51
 von Hippel–Lindau syndrome, 41–2
 fat
 containing AML
 macroscopic, 75–6
 minimal, 78
 solid renal masses NOT containing recognizable, 76–7
 FDG, *see* 18-fluorine-2-deoxy glucose (FDG)
 fine needle ablation biopsy (FNAB), 119–20
 see also ablation; biopsy
 18-fluorine-2-deoxy glucose (FDG)
 FDG-PET, 83–4
 metastatic disease staging and, 104–6
 FNAB, *see* fine needle ablation biopsy (FNAB)
 focal renal biopsy
 complications after, 121
 contemporary indications for, 113

- core biopsy versus fine needle ablation, 119–20
- diagnostic performance of
 - focal cystic tumor renal biopsy, 120
 - focal solid renal biopsy, 118–20
- fumarate hydratase (FH) gene, 49
 - see also* hereditary leiomyomatosis renal cell carcinoma (HLRCC)
- genetics
 - Birt–Hogg–Dubé syndrome, 45
 - familial renal oncocytoma, 54
 - hereditary leiomyomatosis renal cell carcinoma (HLRCC), 49
 - hereditary papillary renal carcinoma, 47
 - hyperparathyroidism-jaw tumor (HPT-JT) syndrome, 52
 - medullary carcinoma of kidney, 55
 - translocation of chromosome 3, 55
 - tuberous sclerosis complex (TSC), 50–1
 - von Hippel–Lindau syndrome, 41
- glomerular filtration rate (GFR), 212
- growth aspects (renal cancers differentiation from other masses), 82–3
- hereditary leiomyomatosis renal cell carcinoma (HLRCC)
 - clinical features, 49
 - genetics, 49
 - imaging, 49–50
 - see also* hereditary renal cancer; renal cell carcinoma (RCC)
- hereditary papillary renal carcinoma (HPRC)
 - clinical features, 47–8
 - genetics, 47
 - imaging, 48
 - type 1 RCC, 47
 - see also* Birt–Hogg–Dubé (BHD) syndrome; von Hippel–Lindau (VHL) syndrome
- hereditary renal cancer, 38
 - management
 - diagnosis, 56–7
 - genetic counseling, 56–7
 - medical treatment, 59
 - minimally invasive treatments, 58–9
 - screening, 56–7
 - surgery options, 58
 - treatment options, 57–8
 - syndromes, 40
 - Birt–Hogg–Dubé syndrome, 45–6
 - hereditary leiomyomatosis renal cell carcinoma, 49–50
 - hereditary papillary renal carcinoma, 47–8
 - hyperparathyroidism-jaw tumor (HPT-JT), 52–3
 - tuberous sclerosis complex, 50–2
 - von Hippel–Lindau syndrome, 41–4
- HIF-1, *see* hypoxia inducible factor-1 (HIF-1)
- high intensity focused ultrasound (HIFU), 169
 - see also* ablation
- histochemical stains, 21
- histochemistry, immunohistochemistry, 21–2
- histological subtype, renal tumor, 24–5
- histology, RCC, 3
- HLRCC, *see* hereditary leiomyomatosis renal cell carcinoma (HLRCC)
- hormonal therapies, 9
 - see also* chemotherapy; immunotherapy; targeted therapies
- HPRC, *see* hereditary papillary renal carcinoma (HPRC)
- HPT-JT, *see* hyperparathyroidism-jaw tumor (HPT-JT)
- hypoxia inducible factor-1 (HIF-1), 2
- hyperparathyroidism-jaw tumor (HPT-JT), 52–3
- IFN, *see* interferon gamma (IFN)
- image-guided radiotherapy (IGRT), 7
- imaging
 - Birt–Hogg–Dubé syndrome, 46
 - common renal cancer, 135
 - familial renal oncocytoma, 54
 - hereditary leiomyomatosis renal cell carcinoma (HLRCC), 49–50
 - hereditary papillary renal carcinoma, 48
 - hyperparathyroidism-jaw tumor (HPT-JT) syndrome, 53
 - medullary carcinoma of the kidney, 56
 - translocation of chromosome 3, 55
 - tuberous sclerosis complex (TSC), 51–2
 - unusual renal cancer, 126
 - von Hippel–Lindau syndrome, 42–4
 - see also* computed tomography (CT); positron emission tomography (PET)
- immunochemotherapy, RCC, 1
- immunocompromised, renal malignancy in, 147–8
- immunohistochemistry, 21–2
- immunotherapy, 9
 - see also* chemotherapy; hormonal therapies
- IMRT, *see* intensity modulation of radiotherapy (IMRT)
- indeterminate masses, patients with, 30–1
 - see also* biopsy
- infections, patients with possible, 29
- inferior vena cava (IVC), 1
- infiltrative renal masses, 85
- inherited renal cancer, 38
 - genetics, 39
 - syndromes without a known genetic defect, 53
 - familial renal oncocytoma, 54
 - medullary carcinoma of kidney, 55–6
 - translocation of chromosome 3, 55
 - see also* renal cancer; renal cell carcinoma (RCC)
- intensity modulation of radiotherapy (IMRT), 7
- interferon gamma (IFN), 165
- intravenous urography (IVU), 138
- invasion
 - adrenal, 102–3
 - collecting system, 26

230 Index

- invasion (cont.)
 - lymphovascular, 100–1
 - vascular, 25
 - venous, 99
- invasive treatments
 - hereditary renal cancers management, 58–9
 - minimally, 58–9
- IVC, *see* inferior vena cava (IVC)
- IVU, *see* intravenous urography (IVU)
- Kaposi's sarcoma, 149
- Ki67, 5
- kidney disease
 - chronic, 211–13
 - contrast, 211–13
- kidney tumor recurrence, contralateral, 188–9
- laparoscopic nephrectomy, 6
 - partial, 163
 - radical, 157
 - see also* surgery
- laparoscopic ultrasound, 223
 - see also* nephron-sparing surgery (NSS)
- laser photocoagulation, 169
 - see also* ablation
- leiomyomatosis renal cell carcinoma, hereditary
 - clinical features, 49
 - genetics, 49
 - imaging, 49–50
- lesions characterization, too small, 84–5
- liver tumor recurrence, 188
- localized carcinoma, clinically, 26, 27
- localized RCC
 - radiotherapy role, 6–7
 - surgery role, 5–6
 - see also* metastatic RCC
- lung tumor recurrence, 187
- lymphadenectomy, 156
 - see also* surgery
- lymphoma, 142–3
 - AIDS-related lymphoma (ARL), 148–9
 - CT patterns of
 - contiguous retroperitoneal extension, 145–6
 - diffuse renal enlargement, 144
 - multiple masses, 143
 - perirenal renal mass, 145
 - solitary renal mass, 144
 - renal cancer versus, 80
 - see also* renal cancer; renal cell carcinoma (RCC)
- lymphovascular invasion, 100–1
 - see also* invasion
- macroscopic fat-containing angiomyolipomas, 75–6
- magnetic resonance imaging (MRI)
 - nephron-sparing surgery and, 203–4, 209–11
 - for renal cancer diagnosis, 64–5
 - staging and, 93
 - for venous invasion assessment, 99
- malignant renal tumors
 - benign renal tumors
 - renal adenoma versus carcinoma, 19–20
 - renal carcinoma versus oncocytoma, 20
 - WHO classification, 17–19
 - see also* renal cancer
- markers, molecular, 27
- masses, renal, 68
 - for assessing enhancement, 68–9
 - biopsy for
 - indeterminate masses, 30–1
 - renal mass characterization, 27–9
 - differentiating mass from another abnormality, 67
 - differentiating renal cancers from other renal masses
 - growth aspects, 82–3
 - imaging aspect, 70–80
 - metabolism aspects, 82
 - heterogeneity, 68
 - infiltrative, 85
 - multiple masses, 143
 - perirenal renal mass, 145
 - solid renal masses, 76–7
 - solitary renal mass, 144
 - see also* radiological diagnosis of renal cancer
- maximum intensity projection images (MIPs), 208
 - see also* nephron-sparing surgery (NSS)
- MCRCC, *see* multilocular cystic renal cell carcinoma (MCRCC)
- MDCT, *see* multi-detector computed tomography (MDCT)
- medullary carcinoma
 - clinical features, 55
 - genetics, 55
 - imaging, 56
 - see also* renal cell carcinoma (RCC)
- Memorial Sloan Kettering Cancer Centre, *see* MSKCC
- system
 - metabolism aspects for differentiating renal cancers
 - from other masses, 82
- metastasectomy, 165
 - see also* surgery
- metastases, 101–2
 - staging, PET for, 105–7
 - surgery, 164–5
 - see also* M staging
- metastatic RCC
 - chemotherapy, 9
 - hormonal therapies, 9
 - immunotherapy role, 9
 - nephrectomy, 7
 - radiotherapy role, 9
 - surgery role, 7–9
 - targeted therapies role, 10–13
 - see also* localized RCC; renal cell carcinoma (RCC)
- MET proto-oncogene, 47
 - see also* hereditary papillary renal carcinoma (HPRC)
- microscopy, electron, 21
 - see also* imaging

- minimal fat containing AML, 78
- minimally invasive treatments, hereditary renal cancers management and, 58–9
- molecular markers, 27
- MRI, *see* magnetic resonance imaging (MRI)
- MSKCC system, 4
- M staging
 - adrenal invasion, 102–3
 - metastases, 101–2
 - pulmonary nodules, 103–4
 - see also* N staging
- multi-detector computed tomography (MDCT), 64–8, 97
- multilocular cystic renal cell carcinoma (MCRCC), 133–5
 - see also* renal cell carcinoma (RCC)
- multiplanar reformatted images (MPR), 208
- see also* nephron-sparing surgery (NSS)
- multiple masses, 143
 - see also* masses, renal
- nephrectomy
 - laparoscopic
 - partial, 6, 163, 193–4
 - radical, 155–7
 - metastatic RCC and, 7
 - open partial, 159–63
 - radical (RN), 155–6
 - surveillance post nephron-sparing surgery, 193–4
 - surveillance post-partial, 193–4
 - surveillance post-radical
 - expected postoperative appearance, 191
 - signs of recurrent or residual tumor, 192
 - see also under* nephron-sparing surgery (NSS)
- nephrographic phase (NP), 65–6
- nephron-sparing surgery (NSS), 203
 - 2- and 3-dimensional reformations, 213–21
 - chronic kidney disease and, 211–13
 - computed tomography (CT) and, 204–8
 - contrast kidney disease and, 211–13
 - laparoscopic ultrasound and, 223
 - MRI and, 209, 210, 211
 - open partial nephrectomy, 159–63
 - radiological guidance during, 222–3
 - surveillance post
 - expected postoperative appearances, 193
 - signs of recurrent or residual tumor, 194
 - see also* nephrectomy
- N staging, 100–1
 - see also* invasion; M staging
- oncocytoma
 - carcinoma versus, 20
 - familial renal
 - clinical features, 54
 - genetics, 54
 - imaging, 54
 - renal cancer versus, 78, 79
 - see also* renal cancer
- open partial nephrectomy, 159–63
 - see also* nephrectomy; nephron-sparing surgery (NSS)
- papillary cancers
 - Type I, 80
 - Type II, 81
- papillary renal cell carcinomas (PRCC), 127–30
 - hereditary
 - clinical features, 47–8
 - genetics, 47
 - imaging, 48
 - type 1 RCC, 47
- parenchymal cancers, adult renal, 17
- partial nephrectomy (PN), 6, 163
 - laparoscopic, 163
 - open, 159–63
 - surveillance post, 194
 - see also* nephron-sparing surgery (NSS)
- pathological prognostic factors (renal tumors), 22
 - collecting system invasion, 26
 - histological subtype, 24, 25
 - pathological stage, 22
 - tumor grade, 24
 - tumor necrosis, 25
 - tumor size, 23
 - vascular invasion, 25
- perirenal renal mass, 145
 - see also* masses, renal
- PET, *see* positron emission tomography (PET)
- photocoagulation, laser, 169
 - see also* ablation
- PN, *see* partial nephrectomy (PN)
- positron emission tomography (PET)
 - FDG-PET, 83–4, 104–6
 - PET-FDG-PET, 104
 - staging and, 94
 - metastatic disease, 105–7
 - primary tumor, 104–5
 - see also* computed tomography (CT); imaging
- post-transplant lymphoproliferative disorder (PTLD), 147
- PRCC, *see* papillary renal cell carcinomas (PRCC)
- primary tumor staging, 104–5
- prognostic algorithms
 - biopsy for renal mass characterization
 - established indications for biopsy, 28
 - extrarenal cancer patients, 28
 - patients with possible infections, 29
- renal tumors, 26
 - biopsy for renal mass characterization, 27–8
 - molecular markers, 27
 - renal cancer subtypes grouped, 26
 - systems for conventional (clear cell), clinically localized carcinoma, 26–7
- prognostic biomarkers, RCC, 5
- prognostic factors
 - RCC, 2–3
 - renal tumors, 22
 - collecting system invasion, 26

232 Index

- prognostic factors (cont.)
 - histological subtype, 24–5
 - pathological stage, 22
 - tumor grade, 24
 - tumor necrosis, 25
 - tumor size, 23
 - vascular invasion, 25
- PTLD, *see* post-transplant lymphoproliferative disorder (PTLD)
- pulmonary nodules, 103–4
 - see also* M staging
- radical nephrectomy (RN)
 - surgery and, 155–6
 - surveillance post
 - expected postoperative appearance, 191
 - signs of recurrent or residual tumor, 192
 - see also* nephrectomy
- radiofrequency ablation (RFA), 169–70
 - biopsy and, 30
 - image-guidance and tumor targeting aspects, 176–7
 - limitations and challenges, 175–6
 - results, 173–5
 - surveillance post, 195–7
 - techniques, 170–1
 - thermal injury to adjacent or critical structures (challenges), 176
 - troubleshooting, 171–3
 - see also* ablation
- radiographic surveillance, 190
 - see also* renal cancer
- radiological diagnosis of renal cancer, 64
 - absolute attenuation measurements, 67–8
 - cancer detection, 66
 - computed tomography (CT) technique, 64–5
 - de-enhancement, 69
 - differentiating mass from another abnormality, 67
 - differentiating renal cancers from other renal masses
 - FDG-PET, 83–4
 - growth aspects, 82–3
 - metabolism aspects, 82
 - enhancement limitations, 69–70
 - imaging for differentiating renal cancers from other renal masses, 70
 - complex renal cysts, 71–4
 - macroscopic fat-containing angiomyolipomas, 75–6
 - minimal fat containing AML and renal masses, 78
 - renal cancer versus oncocytoma, 78–9
 - renal cancer versus renal lymphoma, 80
 - simple renal cysts, 71
 - solid renal masses NOT containing recognizable fat, 76–7
 - infiltrative renal masses, 85
 - lesions characterization, too small, 84–5
 - masses for enhancement, assessing, 68–9
 - mass heterogeneity, 68
 - MRI technique, 64–5
 - renal cancer subtypes differentiation, 80–1
 - renal enhancement phases
 - corticomedullary phase (CMP), 65
 - excretory phase (EP), 65
 - nephrographic phase (NP), 65
 - vascular phase (VP), 65
 - radiological guidance during nephron-sparing surgery, 222–3
- radiotherapy
 - conformal, 7
 - image-guided radiotherapy (IGRT), 7
 - intensity modulation of radiotherapy (IMRT), 7
 - see also* imaging
- RCC, *see* renal cell carcinoma (RCC)
- recurrent tumor
 - likelihood of, 185
 - sites, 186
 - bone, 187–8
 - contralateral kidney, 188–9
 - liver, 188
 - locally, 189
 - lung, 187
 - surveillance
 - post nephron-sparing surgery, 194
 - post radical nephrectomy, 192
 - post thermal ablation, 199
- renal adenoma versus carcinoma, 19–20
- renal cancer
 - ablation, 168
 - cryoablation, 175
 - cryotherapy, 168–9
 - HIFU, 169
 - laser photocoagulation, 169
 - radiofrequency, 169–75
- AIDS-related lymphoma (ARL) and, 148–9
- biopsy for, 112–21
- chromophobe RCC (CHRC), 131
- collecting duct carcinomas (CDRCC), 131–2
- common, 135
- CT patterns of renal lymphoma
 - contiguous retroperitoneal extension, 145–6
 - diffuse renal enlargement, 144
 - multiple masses, 143
 - perirenal renal mass, 145
 - solitary renal mass, 144
- differentiating mass from another abnormality, 67
- growth aspects for differentiating cancer from other masses, 82–3
- hereditary
 - management, 56–9
 - medical treatment, 59
 - minimally invasive treatments, 58–9
 - surgery options, 58
 - treatment options, 57–8
- hereditary renal cancer syndromes, 40
 - Birt–Hogg–Dubé syndrome, 45–6
 - hereditary leiomyomatosis renal cell carcinoma, 49–50

- hereditary papillary renal carcinoma, 47–8
- hyperparathyroidism-jaw tumor (HPT-JT), 52–3
- tuberous sclerosis complex, 50–2
- von Hippel–Lindau syndrome, 41–44
- imaging
 - common, 135
 - unusual, 126
- immunocompromised, renal malignancy in, 147–8
- inherited (without a known genetic defect), 53
 - familial renal oncocytoma, 54
 - medullary carcinoma of kidney, 55–6
 - translocation of chromosome 3, 55
- inherited renal cancer, 39
- macroscopic fat-containing angiomyolipomas and, 75–6
- management, biopsy for, 112–21
- metabolism aspects for differentiating cancer from other masses, 82
- minimal fat containing AML and, 78
- multifocal cystic renal cell carcinoma (MCRCC), 133–5
- of non-renal cell origin, 135–6
 - lymphoma, 142–3
 - squamous cell carcinoma, 141–2
 - transitional cell carcinoma, 136–8, 140–1
- papillary renal cell carcinomas (PRCC), 127–30
- post-treatment surveillance
 - high risk factors, 186
 - post-cryoablation, 198–9
 - post-RFA, 196–7
 - radiographic surveillance, 190
 - recurrence sites, tumor, 186–9
 - recurrent renal cancer, 185
 - surveillance post nephron-sparing surgery, 193–4
 - surveillance post radical nephrectomy, 191–2
 - surveillance post thermal ablation, 195–9
- radiological diagnosis, 64
 - absolute attenuation measurements, 67–8
 - cancer characterization, 67–70
 - cancer detection, 66
 - computed tomography (CT) technique, 64–5
 - de-enhancement, 69
 - differentiating renal cancers from other renal masses, 70, 82–4
 - enhancement limitations, 69–70
 - imaging for differentiating renal cancers from other renal masses, 70–80
 - infiltrative renal masses, 85
 - lesions characterization, too small, 84–5
 - masses for enhancement, assessing, 68–9
 - mass heterogeneity, 68
 - MRI technique, 64–5
 - renal cancer subtypes differentiation, 80–1
 - renal enhancement phases, 65
- recurrent tumor, likelihood of, 185
- recurrent tumor sites, 186
 - bone, 187–8
 - contralateral kidney, 188–9
 - liver, 188
 - locally, 189
 - lung, 187
- renal cysts
 - complex, 71–4
 - simple, 71
- solid renal masses NOT containing recognizable fat, 76–7
- staging
 - history, 91
 - metastatic disease, 105–7
 - M staging, 101–4
 - N staging, 100–1
 - PET for, 104–7
 - primary tumor, 104–5
 - techniques, 92–4
 - TNM staging system, 92
 - T staging, 94–100
 - venous invasion assessment, 97–9
- subtypes differentiation, 80–1
 - type I papillary cancers, 80
 - type II papillary cancers, 81
- surgery for, 155
 - adrenalectomy, 157
 - laparoscopic radical nephrectomy, 157
 - lymphadenectomy, 156
 - metastasectomy, 165
 - metastatic disease, 164–5
 - nephron-sparing surgery, 159–63
 - radical nephrectomy (RN), 155–6
- unusual, 126
 - CDRCC, 131–2
 - CHRC, 131
 - MCRCC, 133–5
 - origin, 127
 - PRCC, 127–30
 - versus oncocytoma, 78–9
 - versus renal lymphoma, 80
 - WHO classification, 128
 - see also* renal cell carcinoma (RCC); renal tumor
- renal cancer subtypes grouped, 26
- renal cell carcinoma (RCC), 1
 - chromophobe (CHRC), 131
 - clear cell (CCRCC), 127
 - clinical risk stratification, 3–5
 - collecting duct carcinomas (CDRCC), 131–2
 - epidemiology, 1–2
 - hereditary leiomyomatosis (HLRCC), 49–50
 - hereditary papillary renal carcinoma (HPRC), 47–8
 - immunotherapy, 1
 - localized
 - radiotherapy role, 6–7
 - surgery role, 5–6
 - management
 - chemotherapy, 9
 - hormonal therapies, 9
 - immunotherapy, 9–10
 - localized RCC, 5–7
 - metastatic RCC, 7–13

234 Index

- renal cell carcinoma (RCC) (cont.)
 - radiotherapy, 6–7, 9
 - surgery role, 5–9
 - targeted therapies, 10–13
- metastatic
 - chemotherapy role, 9
 - hormonal therapies role, 9
 - immunotherapy role, 9–10
 - radiotherapy role, 9
 - surgery role, 7–9
 - targeted therapies role, 10–13
- multilocular cystic (MCRCC), 133–5
- oncocytoma versus, 20
- papillary (PRCC), 127–30
- prognostic biomarkers, 5
- prognostic factors, 2–3
- TNM classification of, 3
- tumor histology, 3
- WHO subtype classification of, 2
- see also* renal cancer; renal tumor; squamous cell carcinoma (SCC)
- renal cysts
 - complex, 71–4
 - simple, 71
- renal enhancement phases
 - cortico-medullary phase (CMP), 65–6
 - excretory phase (EP), 65–6
 - nephrographic phase (NP), 65–6
 - vascular phase (VP), 65–6
- renal mass
 - characterization, biopsy for, 27
 - advanced tumors patients, 28
 - established indications for biopsy, 28
 - extrarenal cancer patients, 28
 - patients with possible infections, 29
 - infiltrative, 85
 - multiple, 143
 - perirenal, 145
 - solitary, 144
- renal parenchymal cancers, adult, 17
- renal tumor
 - benign
 - renal adenoma versus carcinoma, 19–20
 - renal carcinoma versus oncocytoma, 20
 - biopsy for
 - benign tumors, 29–30
 - indeterminate masses, 30–1
 - radio-frequency ablation, patients undergoing, 30
 - electron microscopy for, 21
 - histochemical stains for, 21
 - immunohistochemistry, 21–2
 - malignant
 - renal adenoma versus carcinoma, 19–20
 - renal carcinoma versus oncocytoma, 20
 - pathological prognostic factors, 22
 - collecting system invasion, 26
 - histological subtype, 24–5
 - pathological stage, 22
 - tumor grade, 24
 - tumor necrosis, 25
 - tumor size, 23
 - vascular invasion, 25
 - prognostic algorithms, 26
 - biopsy for renal mass characterization, 27–8
 - molecular markers, 27
 - renal cancer subtypes grouped, 26
 - systems for conventional (clear cell), clinically localized carcinoma, 26–7
 - WHO classification, 17–19
 - see also* renal cancer; renal cell carcinoma (RCC)
- residual tumor
 - surveillance post nephron-sparing surgery, 194
 - surveillance post radical nephrectomy, 192
 - surveillance post thermal ablation, 199
 - see also* renal tumor
- retroperitoneal extension, contiguous, 145–6
- RFA, *see* radiofrequency ablation (RFA)
- risk stratification, RCC, 3–5
- RN, *see* radical nephrectomy (RN)
- SCC, *see* squamous cell carcinoma (SCC)
- sclerosis complex, tuberous
 - clinical features, 51
 - genetics, 50–1
 - imaging, 51–2
- screening, hereditary renal cancers management and, 56
- simple renal cysts, 71
 - see also* complex renal cysts
- single-shot fast spin-echo (SSFSE) images, 65
- solid renal biopsy, focal, 118–20
- solid renal masses NOT containing recognizable fat, 76–7
- solitary renal mass, 144
- sorafenib, 12
- squamous cell carcinoma (SCC), 141–2
- SSFSE, *see* single-shot fast spin-echo (SSFSE) images
- staging, 91
 - history, 91
 - M staging
 - adrenal invasion, 102–3
 - metastases, 101–2
 - pulmonary nodules, 103–4
 - N staging, 100–1
 - PET for
 - metastatic disease, 105–7
 - primary tumor, 104–5
 - techniques, 92–4
 - TNM, 4, 92
 - T staging, 94–5
 - T1/T2 disease, differentiating, 94–5
 - T2/T3 disease, differentiating, 95–6
 - T3b/c disease, identifying, 97
 - T4 disease, 99–100
- venous invasion assessment and
 - CT for, 97–9
 - MRI for, 99
 - ultrasound (US) for, 99

- stains, histochemical, 21
 - see also* renal tumor
- sunitinib, 12
- sunitinib maleate, 11
- surgery, 155
 - adrenalectomy, 157
 - hereditary renal cancers management and, 58
 - laparoscopic radical nephrectomy, 157
 - lymphadenectomy, 156
 - metastasectomy, 165
 - for metastatic disease, 164–5
 - nephron-sparing surgery
 - laparoscopic partial nephrectomy, 163
 - open partial nephrectomy, 159–63
 - radical nephrectomy (RN), 155–6
- surveillance (renal cancer), post treatment, 185
 - post nephron-sparing surgery, 193–4
 - post radical nephrectomy, 191–2
 - post thermal ablation, 195
 - post-cryoablation, 198–9
 - post-RFA, 196–7
 - radiographic surveillance, 190–1
- targeted therapies, 10–13
 - see also* hormonal therapies; metastases
- TCC, *see* transitional cell carcinoma (TCC)
- temsirolimus, 12
- thermal ablation, surveillance post, 195
 - post-cryoablation, 198–9
 - post-RFA, 196–7
 - signs of recurrent or residual tumor, 199
 - see also* cryoablation; radiofrequency ablation (RFA)
- TNM classification
 - renal tumors, 3
 - upper tract TCC, 137
- TNM staging system, 4, 92
 - see also* staging
- transitional cell carcinoma (TCC), 136–41
- translocation of chromosome 3
 - clinical features, 55
 - genetics, 55
 - imaging, 55
 - see also* inherited renal cancer
- transplantation, renal tumor after renal, 147–8
- TSC, *see* tuberous sclerosis complex (TSC)
- T staging
 - T1/T2 disease, differentiating, 94–5
 - T2/T3 disease, differentiating, 95–6
 - T3b/c disease, identifying, 97
 - T4 disease, 99–100
- tuberous sclerosis complex (TSC)
 - clinical features, 51
 - genetics, 50–1
 - imaging, 51–2
 - TSC1 mutations, 50–1
 - TSC2 mutations, 50–1
- tumor
 - advanced, 28
 - grade, 24
 - histology, RCC, 3
 - necrosis, 25
 - recurrence
 - bone, 187–8
 - contralateral kidney, 188–9
 - likelihood of, 185
 - liver, 188
 - locally, 189
 - lung, 187
 - size, 23
 - see also* renal tumor
- two-hit hypothesis, 39
 - see also* hereditary renal cancer
- type I papillary cancers, 80
- type II papillary cancers, 81
- UCLA system, 4
- ultrasound (US)
 - guidance during nephron-sparing surgery, 222–3
 - venous invasion assessment and, 99
- unusual renal cancers, 126
 - CDRCC, 131–2
 - CHRC, 131
 - MCRCC, 133–5
 - origin, 127
 - PRCC, 127–30
 - see also* renal cancer
- vascular endothelial growth factor (VEGF), 2, 10
- vascular invasion, renal tumor and, 25
- vascular phase (VP), 65–6
- VEGF, *see* vascular endothelial growth factor (VEGF)
- vena cava, inferior, 1
- venous invasion
 - CT for, 97–9
 - MRI for, 99
 - ultrasound (US) for, 99
 - see also* invasion
- von Hippel–Lindau (VHL) gene, 2
- von Hippel–Lindau (VHL) syndrome
 - clinical features, 41–2
 - genetics, 41
 - imaging, 42–4
 - type 1, 41
 - type 2, 41
 - type 2 A, 42
 - type 2 B, 42
 - type 2 C, 42
 - see also* Birt–Hogg–Dubé (BHD) syndrome
- WHO classification, renal cancer, 128